

21 October 2005

Dear Shareholder,

Company Update and Share Purchase Plan Reminder

I am writing to provide an update to Resonance Health's recent progress and also to remind you about the Share Purchase Plan (SPP) recently approved by your Board.

As highlighted in the annual report (enclosed with this letter) the commercial progress made over the last 18 months has been profound. This period has seen us transition from a start-up company, nurtured for 4 years in the Physics Department at the University of Western Australia, to become an operational healthcare service provider selling FerriScan®, our world leading diagnostic test for liver iron measurement, to customers around the world.

With the challenges of finishing our development program for FerriScan, negotiating major regulatory hurdles and securing the support of significant and influential early customers, opinion leaders and partners behind us, we now look forward to investing our time and efforts to growing our revenue stream to the point that the company is self-sustaining, and beyond.

This marketing phase of our development is not without its challenges. Significant uptake of any new medical technology is dependent on many factors. The most significant of these are:

- Adoption and endorsement by opinion leaders, and;
- Third party reimbursement.

In the case of opinion leaders, we have several of the worlds leading specialists represented on our Medical Advisory Board. These individuals are already making their contributions felt through education of their peers as to the clinical merits of FerriScan. For instance, last week, Prof. John Olynyk spoke about FerriScan at the Haematology Society of Australia and New Zealand meeting in Sydney. Similar presentations, with appropriate support from our Marketing Department, will occur later in the year at the meetings of the American Association for the Study of Liver Disease and the American Society of Hematology. Some 20,000 specialists will be attending these meetings, providing the ideal opportunity to expand the global awareness of, and increased referrals for, FerriScan.

On the reimbursement front, Resonance Health recently announced that the Western Australian State Government will provide FerriScan at no direct cost to patients. This first reimbursement milestone represents a cornerstone precedent, supporting adoption of similar arrangements with other States in Australia, as well as other health authorities around the world. We continue to progress reimbursement negotiations as a major priority.

In short, the clinical value of FerriScan is now being recognised by many stakeholders, including clinicians, the pharmaceutical industry (through our relationship with Novartis), health authorities, patients and patient interest groups.

Our current and expanding associations with major radiology service providers will ensure that we have appropriate distribution channels established to support widespread uptake of FerriScan. Appropriate investment into marketing and sales related activities will translate to sustainable revenue growth and value to all shareholders.

I must take this opportunity to apologise for the omission of the Stamped Addressed Envelope (SAE) with the papers relating to the SPP. An SAE is enclosed with this letter, and I would encourage those of you who have not as yet taken up the offer, to do so and thereby further support the company's ability to accelerate its growth.

The closing date for application under the SPP is 4th November 2005.


If you haven't already done so, please visit our new website at www.resonancehealth.com which provides valuable information about Resonance Health and FerriScan. For your convenience, I enclose with this letter extracts from recent major announcements regarding our commercial progress.

Thank you once again for your continued support for Resonance Health. I look forward to providing you with further updates about our commercial progress in the future.

Yours faithfully

A handwritten signature in black ink, appearing to read 'J Williams', with a long horizontal flourish extending to the right.

Dr James Williams
Managing Director



The Manager
Company Announcements
Australian Stock Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000

04 October 2005

Dear Sir,

Resonance Health awarded WA State Government Health Supply Contract

Key Points:

- **WA Patients to access FerriScan® at no direct cost**
- **WA State Government to reimburse Resonance Health with commercial fee**
- **FerriScan to replace liver biopsy for Liver Iron Concentration (LIC) measurements**
- **Potential for other States to follow contract model**

4th October 2005: Resonance Health Ltd (ASX: RHT) today announced that its wholly-owned subsidiary Resonance Health Analysis Services (RHAS), has been awarded a Department of Health, Government of Western Australia (WA) Health supply contract.


The contract ensures the supply of the FerriScan® technology to all capable public hospital Magnetic Resonance Imaging (MRI) centres in the State. The first MRI centre to offer FerriScan as part of the contract is located at Fremantle Hospital.

Patients will now be able to access FerriScan through the WA public hospital system with no direct cost to the patient. Costs associated with the provision of the FerriScan service are reimbursed in full under the contract, with RHAS receiving its standard commercial fee for the provision of the FerriScan service.

“We anticipate that this supply contract in WA will provide a foundation to expand the provision of a reimbursed FerriScan service into other States, allowing greater access to FerriScan and improved health outcomes for people at risk from the debilitating effects of iron overload,” said Dr James Williams, Managing Director of Resonance Health.

RHAS was awarded the supply contract after an exemption from tender was granted on the basis that RHAS was the sole supplier of a regulatory cleared MRI method for non-invasive measurement of Liver Iron Concentration (LIC).

Approximately 1 in every 200 Australians have the genetic defect, which causes the iron overload condition “Hereditary Haemochromatosis”. It is estimated that 1000 West Australians are currently under clinical management for their iron overload conditions with thousands more at risk and requiring evaluation.



13 September 2005

The Manager
Company Announcements
Australian Stock Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000

Dear Sir,

Resonance Health Signs MOU with Major US Radiology Chain

13 September 2005: The Resonance Health Group (ASX: RHT) today announced that it has signed a Memorandum of Understanding (MOU) with a major radiology service provider in the United States for a pilot study in preparation for the commercial launch of its MRI-based liver-iron test, FerriScan®.

Under the proposed arrangement, the US radiology chain will perform the MRI component of the FerriScan test and will be responsible for billing and collection activities. Resonance Health will perform the FerriScan analysis. The parties will collaborate on launch plans and reimbursement strategy. US site activation under this collaboration is expected to commence in the fourth quarter of 2005.

The new partnership complements the continuing supply of FerriScan to US centres participating in clinical programs being conducted by Novartis and the Thalassemia Clinical Research Network.


Dr James Williams, Managing Director of Resonance Health said:

“This partnership marks a major milestone in the global commercialisation of FerriScan with the intent to supply FerriScan through a significant number of US MRI sites. With our forthcoming profile activities, including the American Society of Hematology (ASH) and the American Association for the Study of Liver Disease (AASLD), held in the US during November and December respectively, we are positioned to begin building our US revenue stream. ASH and AASLD will attract more than 20,000 of the US and world’s clinical specialists responsible for managing patients with iron disorders.”

FerriScan represents a breakthrough in the diagnosis and management of iron overload, most prominently in disease states such as thalassemia and hemochromatosis which affect over two million people in the US alone.

FerriScan provides doctors with information that is more accurate and cost effective than a liver biopsy or serum blood markers without the need for an invasive procedure and possible dangerous side effects.

Having too much iron in the body and being unable to get rid of this excess is one of the world’s most common hereditary disorders. The disorders, often collectively termed as ‘Iron Overload’, are generally classified as primary (e.g. hereditary hemochromatosis – HHC) or secondary (e.g. acquired – transfusion related iron overload such as thalassemia). Approximately 11 million people globally, who have ‘clinically significant’ iron loading would benefit from improved diagnosis and management of their condition.



The Manager
Company Announcements
Australian Stock Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000

16 August 2005

Dear Sir,

Resonance Health Signs Agreement with US Research Institute to Supply FerriScan®

Key Points

- **Multi-centre international clinical research program to use FerriScan**
- **FerriScan provided as an alternate to liver biopsy**
- **Potential for participating clinical sites to provide expanded FerriScan service**

Perth, Western Australia, 16 August 2005. Resonance Health (ASX:RHT) today announced its wholly-owned subsidiary, Resonance Health Analysis Services, has signed an agreement with the New England Research Institutes (NERI) to provide FerriScan® as part of clinical trials into the iron loading disorder thalassemia. The agreement will see FerriScan used by approximately 13 leading clinical sites in the US and other countries over the next four years.

FerriScan will be used to measure liver iron levels in patients with beta-thalassemia. The information provided by FerriScan will assist clinicians to determine the effects of iron overload on organ injury (including the heart), along with enabling the efficacy of new therapies for beta-thalassemia to be monitored. The work will be undertaken on behalf of the Thalassemia Clinical Research Network (TCRN).

Beta-thalassemia is a genetic blood disorder and a very severe and debilitating form of anaemia, resulting in iron overload due to the requirement for frequent blood transfusions.

Patients involved in this program having a FerriScan will no longer need to have a liver biopsy - a significant step forward in their disease management and quality of life outcomes.

Dr James Williams, Managing Director of Resonance Health said: "We are delighted to be involved in the important work being conducted by NERI/TCRN. The program will allow the clinicians involved to gain first-hand experience in the application of FerriScan to patients with thalassemia, and there is the potential for its use in the broader management of other iron loaded patients under their care."

Resonance Health recently announced the signing of a service agreement with Swiss Pharmaceutical company Novartis, a Collaboration Agreement with the DCA Group in Australia and is in discussions with US radiology providers to assist with the commercial roll-out of FerriScan. Completion of these agreements will position FerriScan to be widely accessible to leading clinicians in Australia, the US and Europe.



The Manager
Company Announcements
Australian Stock Exchange
4th Floor
20 Bridge Street
SYDNEY NSW 2000

5 August 2005

Dear Sir,

**Resonance Health to Provide Expanded FerriScan® Service to Major
Pharmaceutical Company**

Perth, Western Australia, 5 August 2005. Resonance Health (ASX:RHT) today announced the signing of a Frame Agreement between its operating subsidiary, Resonance Health Analysis Services Pty Ltd (formerly Inner Vision Biometrics) and Novartis Pharma AG, a Swiss Pharmaceutical company. Earlier last year, a similar agreement was signed with Novartis Pharmaceuticals Corporation, (New Jersey, US).

Under this agreement, the Resonance Health Group will provide its FerriScan® diagnostic test in connection with clinical studies being undertaken by Novartis Pharma AG. The initial scope of activities is anticipated to generate approximately US\$300,000 revenue for the Resonance Health Group through to the end of 2007, and dependent on Novartis' progress with the trials.

FerriScan® is used in the diagnosis and management of iron overload, in disease states such as thalassemia and hemochromatosis. Iron overload is also found in other disease states such as sickle cell anaemia and a variety of chronic liver diseases.